

ASX/Media Release

Benitec confirms Capital Raising

9 February 2009, Melbourne, Australia: The Directors of Benitec Limited (ASX: BLT) announced today that it has issued a further 13,222,222 ordinary shares and 13,222,222 unlisted options to its major shareholder following the investment of a further \$595,000 by Dr Christopher Bremner.

At the general meeting held on 7 January 2009, shareholders authorised the issue of up to 34,771,010 ordinary shares at an issue price of 4.5 cents (\$0.45) with 34,771,010 free attaching unlisted options (with an exercise price of 10 cents (\$0.10) and an expiry date of 31 December 2012).

This investment brings the total investment in recent months by Dr Bremner to \$1 million.

CONTACT:

BENITEC LTD

Sue MacLeman
Chief Executive Officer
+61 437 211 200

About Benitec

Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. For additional information, please visit www.benitec.com.